Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00421135 | A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer | PHASE1 | COMPLETED | 30 | — | — | Feb 1, 2006 | Oct 1, 2007 | Sep 17, 2009 | 2 | United States |
| Arm | Type | Description |
|---|---|---|
| Single Arm | EXPERIMENTAL | ZIO-201 |
| Name | Type | Description |
|---|---|---|
| ZIO-201 | DRUG | ZIO-201 as a single dose given once every 21 days. This is a dose escalation arm. |
Inclusion Criteria: * Metastatic and /or unresectable disease state after previous standard chemotherapy
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |